Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $122M (up 33.3% year over year) with net income of $40M.
Q3 2025 key financials · XBRL
- Revenue
- $122M
- +33.3% YoY · +43.2% QoQ
- Net income
- $40M
- +999.3% YoY · +69.8% QoQ
- Operating margin
- 61.8%
- EPS (diluted)
- $0.25
- +1150.0% YoY · +78.6% QoQ
Source: XBRL data from the IRONWOOD PHARMACEUTICALS INC (IRWD) Q3 2025 10-Q on SEC EDGAR. USD.
IRONWOOD PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $122.1M, up $30.5M YoY, driven by $30.8M higher U.S. LINZESS net-profit share
- Operating margin 61.8% vs 28.0% YoY; net income $40.1M vs $3.6M
- Best-performing line: LINZESS U.S. net-profit share, up $30.8M; apraglutide R&D $17.8M vs $20.4M
- SG&A $21.9M, down $14.2M; R&D $22.5M, down $7.4M, offset by $2.2M restructuring expense
- Apraglutide confirmatory Phase III trial expected in first half of 2026, subject to FDA alignment in fourth quarter 2025
Risk Factors
- Strategic-alternatives process newly triggered by April 2025 FDA guidance requiring a confirmatory Phase III trial for apraglutide
- Transaction execution risk, with Goldman Sachs engaged and no assurance of favorable terms or completion
- Regulatory risk, confirmatory Phase III trial required for apraglutide NDA approval in SBS-IF patients dependent on PS
- Market risk, failure to complete a strategic alternative could depress Class A common-stock price
- Operational risk, strategic-alternative negotiations may disrupt operations and hinder qualified-personnel retention
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRONWOOD PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.